Erlotinib News and Research

RSS
Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.
Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Researchers identify multiple types of resistance to new targeted lung cancer drug

Researchers identify multiple types of resistance to new targeted lung cancer drug

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

First-line dacomitinib may improve advanced NSCLC survival

First-line dacomitinib may improve advanced NSCLC survival

PD-1, PD-L1 differentially expressed in NSCLC

PD-1, PD-L1 differentially expressed in NSCLC

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

New drug shows promise against treatment-resistant non-small cell lung cancer

New drug shows promise against treatment-resistant non-small cell lung cancer

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Afatinib active against NSCLC nervous system metastases

Afatinib active against NSCLC nervous system metastases

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Antacids linked to reduced erlotinib efficacy

Antacids linked to reduced erlotinib efficacy

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response